Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions

Abstract

Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating complication of multiple chemotherapeutic agents that can affect patients of all ages, across cancer diagnoses. CIPN can persist post-therapy, and significantly impact the health and quality of life of cancer survivors. Identifying patients at risk for CIPN is challenging due to the lack of standardized objective measures to assess for CIPN. Furthermore, there are no approved preventative treatments for CIPN, and therapeutic options for CIPN remain limited once it develops. Biomarkers of CIPN have been studied but are not widely used in clinical practice. They can serve as an important clinical tool to identify individuals at risk for CIPN and to better understand the pathogenesis and avenues for treatment of CIPN. Here we review promising biomarkers of CIPN in humans and their clinical implications.

Introduction

Chemotherapy induced peripheral neuropathy (CIPN) is a common and debilitating toxicity of cancer therapy. CIPN manifests with distal sensory and motor impairments, including pain, paresthesia, numbness, weakness, stiffness, and muscle atrophy (1), and can lead to impaired physical function and quality of life in cancer survivors (2–4). Patients at risk for CIPN range from children to adults, and span multiple cancer diagnoses (1, 5). Classes of chemotherapy implicated in CIPN include platinums, taxanes, vinca alkaloids, proteosome inhibitors, and angiogenesis inhibitors (5). As many a 68% of adult patients receiving neurotoxic chemotherapy develop CIPN, with one third of cases persisting post-therapy (6).

Despite the high prevalence and morbidity associated with CIPN, there are significant barriers to diagnosis and treatment. There is no standardized measure for CIPN, and current measures have limitations (7, 8). Objective measures including nerve conduction studies and the Total Neuropathy Score (TNS) can be invasive and time consuming, while patient-reported measures can be biased by subjective responses (8). Further, there are no approved treatments to prevent CIPN, and limited therapeutic options once it develops (9).

Biomarkers offer a novel approach to objectively identifying and risk-stratifying patients with CIPN and can provide insight into pathogenesis and treatment. Although studies of biomarkers of CIPN have increased over the past decade, they are still not part of routine clinical care. We present a review of promising biomarkers of CIPN in humans, and their implication for clinical care and future studies.

Protein/Molecular Biomarkers of CIPN

Increasing studies are identifying alterations in serum proteins and molecular markers in CIPN patients (Figure 1).

Figure 1

Neurofilament Light Chain (NfL)

NfL is a neuronal cytoskeletal protein released with axonal damage (10). NfL was initially described as a marker of neurodegenerative diseases (11), and later of inherited neuropathies, and CIPN in animal models (10, 12).

Recently NfL has been studied in adults with CIPN. A prospective study of 43 patients receiving oxaliplatin evaluated serum NfL and CIPN severity by nerve conduction studies throughout therapy (13). Mean serum NfL levels increased over time, with significant differences in serum NfL between low grade (0–2) CIPN vs. high grade (≥3) CIPN at 6 months, and a cut-off of 195 pg/ml being 80% sensitive and 86.2% specific to identify high grade CIPN (13).

Brain Derived Neurotrophic Factor (BDNF)

BDNF is a protein that promotes neuronal survival (14, 15). BDNF was associated with CIPN in 25 bortezomib-treated multiple myeloma patients evaluated for CIPN using the reduced Total Neuropathy Score (TNS-r) before and during therapy (16). Eight participants who developed CIPN had lower mean BDNF levels (2.16 ± 0.72 vs. 4.62 ± 0.61 ng/ml, p = 0.007), and were more likely to have a reduction from baseline BDNF (−1.67 ± 0.67 vs. 0.41 ± 0.71, p = 0.02) than those without CIPN (16). Similarly in 91 multiple myeloma patients treated with bortezomib or thalidomide lower BDNF levels during treatment were associated with CIPN by Common Terminology Criteria for Adverse Events (CTCAE), and a cut-point of 9.11 ng/ml was 76% sensitive and 71.4% specific to identify CIPN (17). Correlation between BDNF levels and CIPN by TNS-r was also reported in 22 non-Hodgkin lymphoma patients treated with vincristine (18).

Single nucleotide polymorphisms (SNPs) in BDNF may also confer increased risk for CIPN in individuals with Met/Met or Val/Met vs. Val/Val genotype (17–20). This association has been shown in bortezomib (16), and taxane-treated patients (20). A study of 35 breast cancer patients treated with taxanes, however, found the risk may be due to increased prevalence of baseline neuropathy, with no difference in prevalence of CIPN between genotypes when excluding patients with baseline neuropathy (21). There was also no association between the met-BDNF genotype and CIPN in 22 non-Hodgkin lymphoma patients treated with vincristine (18).

Nerve Growth Factor (NGF)

NGF is a protein that also regulates neuronal survival (22). In 23 cancer patients receiving taxanes or platinums NGF levels decreased after four to six cycles of chemotherapy, and decline was associated with severity of CIPN by nerve conduction studies (23). Similarly in 129 plasma samples from 34 women treated for cervical cancer with paclitaxel and cisplatin, decrease in NGF from baseline was associated with CIPN severity by TNS (24). A prospective study of 45 patients with hematologic malignancies treated with bortezomib, thalidomide, or vincristine, also found there was a significant decrease in NGF in participants who developed CIPN symptoms, whereas there was no change in NGF in participants who did not develop CIPN symptoms (25). In contrast, in a study specifically evaluating neuropathic pain in 60 patients treated with platinum or taxane therapy, the 13 patients who developed painful neuropathy had higher NGF levels post-therapy than those without neuropathic pain (26).

Osteopontin

Osteopontin is a glycoprotein involved in inflammatory pathways and has been implicated in cancer progression (27). It has been described as a marker of inflammation in other neurologic conditions included multiple sclerosis (28), and has also been implicated in neuronal repair (29). In a study of 50 breast cancer patients treated with taxanes evaluated by the TNS-r lower baseline levels of osteopontin were associated with developing moderate or severe CIPN, and baseline osteopontin levels were inversely associated with the magnitude of change in nerve conduction over time (30).

Inflammatory Markers

The immune system has increasingly been implicated in CIPN in animal models (31, 32), but few studies examine the association of immune markers with CIPN in humans. In 67 breast cancer patients treated with taxanes there was a higher peripheral blood neutrophil-to-lymphocyte ratio in patients with CIPN than those without CIPN (33). In an analysis of cytokines in 55 breast cancer patients treated with taxane and platinum chemotherapy, high IFN-γ, IL-1β, and IL-8 and low IL-10 and IL-6 were associated with CIPN symptoms (34).

MicroRNA, Proteomics, and Metabolomics

A recent approach to biomarker discovery in CIPN has included microRNA and exosome sequencing. In a preclinical model, miRNA-124 was associated with CIPN in mice treated with paclitaxel (35). MicroRNA may be a promising marker in humans as well, in cross-sectional analysis of microRNA expression in 84 breast cancer patients treated with paclitaxel, 15 microRNAs were identified with a significant fold change between CIPN and non-CIPN groups, and miRNA-451a was the most discriminatory (36). Mass spectrometry-based proteomic technology is another novel approach to biomarker discovery used to identify protein signatures associated with CIPN. In a study of 17 patients with breast cancer treated with taxanes, 12 protein signatures identified patients who developed CIPN (37).

Genetic Biomarkers of CIPN

Genetic alterations are increasingly studied as predictors of disease toxicity. The following genetic alterations have been implicated in susceptibility to CIPN (Table 1).

Genes Associated With Microtubule Function

Taxanes and vinca alkaloids interfere with microtubule function and may lead to CIPN pathogenesis (1, 73), therefore genes encoding microtubule function have been studied as predictors of CIPN sensitivity. An SNP in CEP72 (rs924607) is associated with CIPN in children and adults (38–41). In 48 adults with acute lymphoblastic leukemia (ALL) receiving vincristine, 75% with the TT genotype developed CIPN vs. 44% with CC or CT genotypes (39). In a combined sample of pediatric ALL patients treated with vincristine in two large therapeutic trials, the TT genotype was also associated with an increased risk for CIPN (38). This finding was replicated when measuring CIPN with nerve conduction studies (41), and in a separate cohort of pediatric ALL patients (40). However, other studies evaluating CEP72 alterations did not find associations with CIPN in cohorts of Spanish and Arab patients treated with vincrisitne (74, 75). Additionally, there was no association of CEP72 alterations with CIPN in patients treated with taxanes (43).

A polymorphism in TUBB2A, encoding tubulin, was associated with CIPN in 1,303 European patients treated with paclitaxel (42). However this finding has not been replicated in other studies of taxanes and vinca alkaloids (43, 76). Individual polymorphisms in MAPT (43, 76) and GSK3B (43) have not been associated with CIPN in patients treated with taxanes or vinca alkaloids, however additive polymorphisms in MAPT and GSK3B were associated with patient and clinician reported CIPN in 454 ovarian cancer patients treated with paclitaxel and carboplatin (43). SNPs in cytoskeletal protein genes, ACTG1 and CAPG, have also been associated with CIPN in pediatric ALL patients treated with vincristine (44).

Genes Associated With Ion Channels

Disturbance in neuronal function through ion channels may also contribute to CIPN, and alterations in these genes have been associated with CIPN sensitivity (1, 73, 77). In 186 Japanese breast and ovarian cancer patients treated with taxanes a SNP in SCN9A, encoding voltage-gated sodium channels, was associated with developing ≥grade 2 CIPN, and predicted CIPN persistence post-treatment (56). In 94 Spanish patients with gastrointestinal cancer treated with oxaliplatin another polymorphism in SCN9A was associated with a lower risk of acute CIPN by neurologic evaluation (57), and in 228 South Indian gastrointestinal cancer patients treated with oxaliplatin it was associated with increased incidence of chronic CIPN (58). In 200 patients with colorectal cancer treated with platinums, polymorphisms in SCN4A and SCN10A that encode voltage-gated sodium channels were associated with CIPN risk and severity (59). SCN10A has also been associated with chronic CIPN (58). Associations of mutations in voltage-gated potassium channels with CIPN have not been identified (78).

Genes Associated With Inherited Neuropathies

Genes implicated in inherited neuropathies have also been examined in relation to CIPN. SBF2, associated with Charcot-Marie-Tooth disease, was associated with CIPN in 213 African American patients treated with paclitaxel (61). However, another prospective study of 58 paclitaxel-treated patients found FZD3 was associated with CIPN, but not SBF2 (61). In a study of 219 breast cancer patients treated with taxanes, FGD4 was associated with CIPN (46). In a large prospective study of 855 patients of European Ancestry receiving paclitaxel, another polymorphism in FGD4 was associated with patient-reported sensory CIPN, which was replicated in two additional cohorts (62). In the replication cohorts a different polymorphism in FZD3 was also associated with sensory CIPN (62). ARHGEF10 was associated with CIPN in a prospective study of 269 cancer patients treated in Alliance N08C1 that analyzed blood samples for 49 Charcot-Marie-Tooth genes (63). These findings were confirmed in 138 patients treated with paclitaxel in Alliance N08CA (64).

Genes Associated With Inflammatory Pathways

There is a growing body of literature suggesting inflammation contributes to CIPN (73, 79, 80), and genetic alterations in inflammatory pathways have been studied in association with CIPN. In 3,431 breast cancer patients treated with paclitaxel a SNP in FCAMR that encodes the FC receptor, trended toward a significant association with CIPN (60). In 139 patients treated with bortezomib, variations in genes regulating immune function, CTLA4 and CTSS, were associated with time to onset of CIPN, with a similar trend for CTLA4 in a validation cohort (55). Bortezomib-neuropathy has also been associated with alterations in IL17RD, IL10RA, and genes in the NF-KB signaling pathway in 646 patients with multiple myeloma (52). Late-onset bortezomib-neuropathy was associated with polymorphisms in other genes in inflammatory pathways, MBL2 and PPARD in 186 myeloma patients (53). In a meta-analysis of pediatric patients treated with vincristine for ALL from two large clinical trials rs7963521, associated with coding of the protein chemerin implicated in inflammatory pathways (66), was associated with CIPN.

Genes Associated With Drug Metabolism and Transport

Polymorphisms in genes involved in chemotherapy metabolism may also increase CIPN sensitivity. In 107 children treated for ALL with vincristine CYP3A5 polymorphisms were associated with CIPN (45). SNPs in CYP2C8 and CYP3A4 were associated with ≥grade 2 CIPN in two studies of breast cancer patients treated with taxanes (46, 47). In 79 breast cancer patients treated with taxanes SNPs in NR1I3 and UGT2B7 involved in drug metabolism were also associated with CIPN (48). In 1,303 patients treated with taxanes, additional SNPs in genes involved in taxane metabolism including, CYP2C8^*4 and CYP1B1^*3, were associated with CIPN, as were, ABCB1 and SLCO1B1, involved in drug transport (42). In multiple myeloma patients treated with bortezomib, alterations in PSMB1, encoding drug binding proteins (55), and ABCC1 and ABCC6, encoding drug transport, were also associated with CIPN (52). However, in a separate study of 369 multiple myeloma patients ABCC1 polymorphisms were not associated with bortezomib-neuropathy, but were associated with vincristine-neuropathy, as was DPYD responsible for drug excertion (53). ABCC1 polymorphisms have also been associated with CIPN in pediatric ALL patients treated with vincristine (40, 50). Alterations in, ABCB1, encoding drug transport, has also been widely associated with CIPN in patients treated with vincristine and taxanes (44, 46, 49–51), and alterations in ABCC2 are associated with CIPN in children treated with vincristine (50). An alteration in ABCG2, involved in oxalate metabolism, was associated with oxaliplatin-induced neuropathy in 206 colon cancer patients (54).

Other Genetic Alterations Associated With CIPN

Genes involved in nervous system development and function, and in cellular repair pathways, have also been associated with CIPN.

Alterations in genes encoding ephrin receptors (EPHA4, EPHA5, EPHA6, EPHA8), a family of tyrosine kinase receptors involved in neural development, are associated with CIPN in patients treated with taxanes (62, 69–71, 81). An SNP in TAC1, encoding neuronal signaling hormones, was associated with CIPN in colon cancer patients treated with oxaliplatin (65). A polymorphisms in COCH, encoding cochlin involved in vestibular function and hearing loss, was associated with CIPN in a study of children with ALL treated with vincristine (82). Alterations in SOX10, involved in neuronal development, and GPX7 were associated with CIPN in 107 survivors of gynecologic cancers treated with taxane or platinum (67). Polymorphisms in genes involved in nervous system function, NFATC1, NFATC4, and EDN1 were associated with CIPN in 646 myeloma patients treated with bortezomib (52), as were TCF4, DYNC1I1, and GJE1 in 139 myeloma patients treated with bortezmib (55). GNGT1 encodes a protein in photoreceptors and has been associated with taxane-CIPN (68, 83).

Alterations in genes associated with DNA repair are also associated with CIPN. SNPs in CCNH, encoding cyclin H, involved in cell cycle progression and DNA repair (84), were associated with CIPN in 206 colon cancer patients (54), and in 228 gastrointestinal cancer patients treated with oxaliplatin (72). In myeloma patients treated with bortezomib, ERCC4 and ERCC3 involved in DNA repair were associated with CIPN (53). In a study of 680 testicular cancer survivors treated with cisplatin, lower expression of DNA repair gene RPRD1B, was associated with an increased risk of CIPN, which was replicated in two independent datasets (85).

Pharmacokinetics and CIPN

Evaluation of drug pharmacokinetics may be another promising approach to identifying CIPN sensitivity.

Taxane Pharmacokinetics

In 24 patients who received 12 weekly 3 or 1 h infusions of paclitaxel, longer duration of paclitaxel concentration >0.05 μM was associated with developing CIPN (86). In another prospective evaluation of 60 breast cancer patients receiving weekly paclitaxel infusions neither peak plasma concentration nor time above concentration of 0.05 μM were associated with CIPN, but were associated with increased toxicity-related treatment disruptions (87). An early study of lung cancer patients treated with paclitaxel also found no association between plasma concentration and neuromuscular or neurosensory outcomes (88).

Vincristine Pharmacokinetics

An early study of pharmacokinetics in 54 children treated with vincristine did not find any association between vincristine clearance and neurotixicy (89). In a subsequent study assessing pharmacokinetics of vincristine in 74 pediatric patients, lower vincristine metabolite concentrations were associated with increased CIPN severity (45). Another study assessed vincristine pharmacokinetics in 35 patients receiving vincristine via push or 1 h infusions and found intercompartment clearance of vincristine was associated with an increased risk of CIPN, however other pharmacokinetic measures including maximum concentration were not associated with an increased CIPN risk (90).

Discussion

We described promising biomarkers of CIPN in humans, including serum proteins, genetic polymorphisms, and drug metabolites. There are several limitations to the current studies and areas for future direction.

Serum protein biomarkers such as NfL, BDNF, NGF, osteopontin, and inflammatory markers have all been associated with CIPN, and may be easily translatable tools for detection and risk profiling in clinical practice (13, 18, 19, 24, 28, 91). However, these studies have been limited by small samples and variation in CIPN measurement between studies. Prospective validation studies of these biomarkers using objective CIPN measures would be helpful in confirming their clinical utility. Additionally, preclinical models should continue to be utilized to identify protein biomarkers that can be validated in humans.

Protein biomarkers can also inform therapeutic options that should continue to be explored. For example, in a study of 60 patients with bortezomib-neuropathy, patients randomized to receive NGF injections had better nerve conduction studies than those who did not receive NGF (92). In paclitaxel-treated rats, losartan had anti-inflammatory activity that resulted in lower inflammatory markers and decreased signs of CIPN (31). In addition to immune pathway targets, there are promising therapeutic targets that have been identified in critical CIPN pathways in animal models (73, 93). Neuronal Calcium Sensor-1 (NCS1), a protein involved in calcium signaling that binds taxanes and vinca alkaloids, decreases in CIPN in animal models (94–96). NCS1 may be a therapeutic target since lithium and ibudilast bind NCS1 and prevent CIPN in animal models (96), and retrospective studies show lithium may prevent CIPN in humans (97). Sterile alpha and TIR motif containing protein (SARM1) is another protein implicated in axonal degeneration in CIPN in preclinical models (73), and SARM1 inhibition may prevent CIPN (98, 99). Therefore, preclinical models can help better understand CIPN mechanisms, not only resulting in biomarker discovery that can be translated to the bedside, but also informing therapeutic strategies to prevent and mitigate CIPN that can be tested in humans.

Genetic polymorphisms are another avenue that offer promise in identifying individuals at risk for CIPN. CEP72 has been identified as a risk factor for CIPN in multiple studies (38, 39, 43), and may help classify upfront risk for toxicity. Future studies should focus on whether treatment modification in at risk individuals alters toxicity and survival outcomes. Other genome wide studies identified numerous polymorphisms that may influence CIPN sensitivity, but few were replicated in multiple cohorts, therefore future studies should focus on replicating these findings. Another limitation of genome wide studies is that they only identify proteins with altered expression, however in other models altered function, rather than expression, of cellular components are proposed to initiate CIPN (93). Future studies should continue to elucidate CIPN pathogenesis through complementary mechanisms of genome wide studies and functional pathway analyses to identify therapeutic targets to mitigate this outcome.

Finally, pharmacokinetics is an evolving way to assess drug response and CIPN susceptibility in individuals receiving neurotoxic chemotherapy. Although current studies report mixed results regarding the ability to identify individuals at risk for CIPN (45, 87, 90), it warrants further exploration. Monitoring individual plasma drug concentration could offer a novel method to ensure adequate dosing for cancer treatment while minimizing risk for CIPN.

A limitation across studies is that there is no standardized method to define CIPN. We found most studies used CTCAE for CIPN grading, which lacks sensitivity and can vary by evaluator (100–102). Patient-reported outcome measures for CIPN have been validated in adults, and may be more sensitive for detection and measurement of change over time than the CTCAE (101–103). However, patient-reported outcomes still have limitations and do not always correlate with clinical assessments (104). It is important that future biomarker research incorporate robust, validated measures for CIPN that ideally combine patient-report and clinical evaluations (104).

Overall, there are many promising biomarkers of CIPN that can be valuable tools to aid in detection, risk stratification, and drug development. Future studies should prioritize large-scale validation of these biomarkers using standardized instruments to measure CIPN and expedite their implementation into clinical practice.

Funding

RR was supported by the National Cancer Institute through the Yale Cancer Prevention and Control Training Program (T32 CA250803), as well as the Yale Pediatric Scholar Program, the William O. Seery Mentored Research Award for Cancer Research, Bank of America, N.A., Trustee, and Hyundai Hope on Wheels Young Investigator Award.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1.

  BjornardKLGilchristLSInabaHDioufBHockenberryMJKadan-LottickNSet al. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. (2018) 2:744–54. 10.1016/S2352-4642(18)30236-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  KandulaTFarrarMACohnRJMizrahiDCareyKJohnstonKet al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol. (2018) 75:980–8. 10.1001/jamaneurol.2018.0963

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  EikelandSASmelandKBMolsFFagerliUMBersvendsenHSKiserudCEet al. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life. Acta Oncol. (2021) 60:911–20. 10.1080/0284186X.2021.1917776

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  van de VeldeMEvan den BergMHKaspersGJLAbbinkFCHTwiskJWRvan der SluisIMet al. The association between vincristine-induced peripheral neuropathy and health-related quality of life in children with cancer. Cancer Med. (2021) 10:8172–81. 10.1002/cam4.4289

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  StaffNPGrisoldAGrisoldWWindebankAJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. (2017) 81:772–81. 10.1002/ana.24951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  SeretnyMCurrieGLSenaESRamnarineSGrantRMacLeodMRet al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. (2014) 155:2461–70. 10.1016/j.pain.2014.09.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  MohrmannCArmerJHayashiRJ. Challenges evaluating chemotherapy-induced peripheral neuropathy in childhood cancer survivors. J Pediatr Oncol Nurs. (2017) 34:106–14. 10.1177/1043454216651016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  HaryaniHFetzerSJWuCLHsuYY. Chemotherapy-induced peripheral neuropathy assessment tools: a systematic review. Oncol Nurs Forum. (2017) 44:E111–e23. 10.1188/17.ONF.E111-E123

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  LoprinziCLLacchettiCBleekerJCavalettiGChauhanCHertzDLet al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. (2020) 38:3325–48. 10.1200/JCO.20.01399

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  MeregalliCFumagalliGAlbertiPCantaACarozziVAChiorazziAet al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol. (2018) 307:129–32. 10.1016/j.expneurol.2018.06.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  RosengrenLEKarlssonJEKarlssonJOPerssonLIWikkelsøC. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. (1996) 67:2013–8. 10.1046/j.1471-4159.1996.67052013.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  SandeliusÅZetterbergHBlennowKAdiutoriRMalaspinaALauraMet al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. (2018) 90:e518–e24. 10.1212/WNL.0000000000004932

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  KimSHChoiMKParkNYHyunJWLeeMYKimHJet al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep. (2020) 10:7995. 10.1038/s41598-020-64511-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  HoferMMBardeYA. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature. (1988) 331:261–2. 10.1038/331261a0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  LipskyRHMariniAM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci. (2007) 1122:130–43. 10.1196/annals.1403.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  AzoulayDLavieDHorowitzNSuriuCGattMEAkriaLet al. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol. (2014) 164:454–6. 10.1111/bjh.12624

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  Szudy-SzczyrekAMlakRBury-KamińskaMMielnikMPodgajnaMKuśmierczukKet al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol. (2020) 191:77–89. 10.1111/bjh.16862

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  AzoulayDNasserRSharonRSimanovichLAkriaLShaoulEet al. Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma. Br J Haematol. (2019) 185:175–7. 10.1111/bjh.15428

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  AzoulayDGiryesSNasserRSharonRHorowitzNA. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism. J Clin Neurol. (2019) 15:511–6. 10.3988/jcn.2019.15.4.511

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  AzoulayDLeiboviciASharoniRShaoulEGrossBBraesterAet al. Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. (2015) 153:703–4. 10.1007/s10549-015-3546-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  LeiboviciASharonRAzoulayD. BDNF Val66Met is associated with pre-existing but not with paclitaxel-induced peripheral neuropathy in an Israeli cohort of breast cancer patients. Isr Med Assoc J. (2018) 20:746–8. https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2018&month=12&page=746

  • Pubmed Abstract
  • Google Scholar

• 22.

  AloeLRoccoMLBianchiPManniL. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. (2012) 10:239. 10.1186/1479-5876-10-239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  De SantisSPaceABoveLCognettiFProperziFFioreMet al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. (2000) 6:90–5. https://aacrjournals.org/clincancerres/article/6/1/90/287777/Patients-Treated-with-Antitumor-Drugs-Displaying

  • Pubmed Abstract
  • Google Scholar

• 24.

  CavalettiGBogliunGMarzoratiLZinconeAPiattiMColomboNet al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. (2004) 15:1439–42. 10.1093/annonc/mdh348

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  YoukJKimYSLimJAShinDYKohYLeeSTet al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS ONE. (2017) 12:e0183491. 10.1371/journal.pone.0183491

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  VelascoRBrunaJBrianiCArgyriouAACavalettiGAlbertiPet al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. (2014) 85:392–8. 10.1136/jnnp-2013-305334

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  CastelloLMRaineriDSalmiLClementeNVaschettoRQuagliaMet al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm. (2017) 2017:4049098. 10.1155/2017/4049098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  AgahEZardouiASaghazadehAAhmadiMTafakhoriARezaeiN. Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis. PLoS ONE. (2018) 13:e0190252. 10.1371/journal.pone.0190252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  WrightMCMiRConnorEReedNVyasAAlspalterMet al. Novel roles for osteopontin and clusterin in peripheral motor and sensory axon regeneration. J Neurosci. (2014) 34:1689–700. 10.1523/JNEUROSCI.3822-13.2014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  PizzamiglioCRipellinoPPrandiPClementeNSaggiaCRossiVet al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin. (2020) 50:47–54. 10.1016/j.neucli.2019.12.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  KalynovskaNDialloMSotakova-KasparovaDPalecekJ. Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy. J Cell Mol Med. (2020) 24:7949–58. 10.1111/jcmm.15427

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  KrukowskiKEijkelkampNLaumetGHackCELiYDoughertyPMet al. CD8+ T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. J Neurosci. (2016) 36:11074–83. 10.1523/JNEUROSCI.3708-15.2016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  YamanouchiKKubaSSakimuraCMoritaMKanetakaKKobayashiKet al. The relationship between peripheral neuropathy induced by docetaxel and systemic inflammation-based parameters in patients with breast cancer. Anticancer Res. (2017) 37:6947–51. 10.21873/anticanres.12160

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  KlecknerIRJuskoTACulakovaEChungKKlecknerASAsareMet al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat. (2021) 189:521–32. 10.1007/s10549-021-06304-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  PengQMechanicJShoiebAPardoIDSchaevitzLFenyk-MelodyJet al. Circulating microRNA and automated motion analysis as novel methods of assessing chemotherapy-induced peripheral neuropathy in mice. PLoS ONE. (2019) 14:e0210995. 10.1371/journal.pone.0210995

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  BenbowJHMannTKeelerCFanCHodsdonMELolisEet al. Inhibition of paclitaxel-induced decreases in calcium signaling. J Biol Chem. (2012) 287:37907–16. 10.1074/jbc.M112.385070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  ChenEICrewKDTrivediMAwadDMaurerMKalinskyKet al. Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS ONE. (2015) 10:e0145816. 10.1371/journal.pone.0145816

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  DioufBCrewsKRLewGPeiDChengCBaoJet al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. (2015) 313:815–23. 10.1001/jama.2015.0894

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  StockWDioufBCrewsKRPeiDChengCLaumannKet al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. (2017) 101:391–5. 10.1002/cpt.506

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  WrightGEBAmstutzUDrogemollerBIShihJRassekhSRHaydenMRet al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. (2019) 105:402–10. 10.1002/cpt.1179

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  KavčičMZečkanovićAJazbecJDebeljakM. Association of CEP72 rs924607 TT genotype with vincristine-induced peripheral neuropathy measured by motor nerve conduction studies. Klin Padiatr. (2020) 232:331–3. 10.1055/a-1213-5995

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  AbrahamJEGuoQDorlingLTyrerJIngleSHardyRet al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. (2014) 20:2466–75. 10.1158/1078-0432.CCR-13-3232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  ParkSBKwokJBAsherRLeeCKBealePSelleFet al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. (2017) 28:2733–40. 10.1093/annonc/mdx491

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  CeppiFLanglois-PelletierCGagnéVRousseauJCiolinoCDe LorenzoSet al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. (2014) 15:1105–16. 10.2217/pgs.14.68

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  EgbelakinAFergusonMJMacGillEALehmannASTopletzARQuinneySKet al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. (2011) 56:361–7. 10.1002/pbc.22845

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  KusTAktasGKalenderMEDemiryurekATUlasliMOztuzcuSet al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther. (2016) 9:5073–80. 10.2147/OTT.S106574

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  HertzDLRoySMotsinger-ReifAADrobishAClarkLSMcLeodHLet al. CYP2C8^*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. (2013) 24:1472–8. 10.1093/annonc/mdt018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  ArbitrioMSciontiFAltomareEDi MartinoMTAgapitoGGaleanoTet al. Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in patients with breast cancer: a case-control study. Clin Pharmacol Ther. (2019) 106:422–31. 10.1002/cpt.1391

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  TanabeYShimizuCHamadaAHashimotoKIkedaKNishizawaDet al. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol. (2017) 79:1179–86. 10.1007/s00280-017-3314-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  Lopez-LopezEGutierrez-CaminoAAstigarragaINavajasAEchebarria-BaronaAGarcia-MiguelPet al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. (2016) 17:731–41. 10.2217/pgs-2016-0001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51.

  SissungTMBaumCEDeekenJPriceDKAragon-ChingJSteinbergSMet al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. (2008) 14:4543–9. 10.1158/1078-0432.CCR-07-4230

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  CampoCDa Silva FilhoMIWeinholdNGoldschmidtHHemminkiKMerzMet al. Genetic susceptibility to bortezomib-induced peripheral neuroropathy: replication of the reported candidate susceptibility loci. Neurochem Res. (2017) 42:925–31. 10.1007/s11064-016-2007-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  BroylACorthalsSLJongenJLvan der HoltBKuiperRde KnegtYet al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. (2010) 11:1057–65. 10.1016/S1470-2045(10)70206-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54.

  CustodioAMoreno-RubioJAparicioJGallego-PlazasJYayaRMaurelJet al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol. (2014) 25:398–403. 10.1093/annonc/mdt546

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55.

  FavisRSunYvan de VeldeHBroderickELeveyLMeyersMet al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics. (2011) 21:121–9. 10.1097/FPC.0b013e3283436b45

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56.

  TanabeYShiraishiSHashimotoKIkedaKNishizawaDHasegawaJet al. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer. (2020) 20:325. 10.1186/s12885-020-06834-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57.

  SerenoMGutiérrez-GutiérrezGRubioJMApellániz-RuizMSánchez-BarrosoLCasadoEet al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. (2017) 17:63. 10.1186/s12885-016-3031-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58.

  PalugullaSThakkarDNKayalSNarayanSKDkharSA. Association of voltage-gated sodium channel genetic polymorphisms with oxaliplatin-induced chronic peripheral neuropathy in south indian cancer patients. Asian Pac J Cancer Prev. (2017) 18:3157–65. 10.22034/APJCP.2017.18.11.3157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59.

  ArgyriouAACavalettiGAntonacopoulouAGenazzaniAABrianiCBrunaJet al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. (2013) 119:3570–7. 10.1002/cncr.28234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60.

  SchneiderBPLiLRadovichMShenFMillerKDFlockhartDAet al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. (2015) 21:5082–91. 10.1158/1078-0432.CCR-15-0586

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  ChenYFangFKidwellKMVangipuramKMarcathLAGerschCLet al. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Pharmacogenomics. (2020) 21:841–51. 10.2217/pgs-2020-0053

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62.

  BaldwinRMOwzarKZembutsuHChhibberAKuboMJiangCet al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. (2012) 18:5099–109. 10.1158/1078-0432.CCR-12-1590

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63.

  BeutlerASKulkarniAAKanwarRKleinCJTherneauTMQinRet al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. (2014) 76:727–37. 10.1002/ana.24265

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64.

  BooraGKKulkarniAAKanwarRBeyerleinPQinRBanckMSet al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. (2015) 357:35–40. 10.1016/j.jns.2015.06.056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65.

  WonHHLeeJParkJOParkYSLimHYKangWKet al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. (2012) 118:2828–36. 10.1002/cncr.26614

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66.

  LiLSajdykTSmithEMLChangCWLiCHoRHet al. Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clin Pharmacol Ther. (2019) 105:1421–8. 10.1002/cpt.1324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67.

  ThomaierLDarstBFJewettPHoffmannCBrownKMakaramAet al. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors. Gynecol Oncol. (2021) 163:578–82. 10.1016/j.ygyno.2021.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68.

  Sucheston-CampbellLEClay-GilmourAIBarlowWEBuddGTStramDOHaimanCAet al. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics. (2018) 28:49–55. 10.1097/FPC.0000000000000318

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69.

  Leandro-GarcíaLJInglada-PérezLPitaGHjerpeELeskeläSJaraCet al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. (2013) 50:599–605. 10.1136/jmedgenet-2012-101466

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70.

  MarcathLAKidwellKMVangipuramKGerschCLRaeJMBurnessMLet al. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Br J Clin Pharmacol. (2020) 86:880–90. 10.1111/bcp.14192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  Apellániz-RuizMTejeroHInglada-PérezLSánchez-BarrosoLGutiérrez-GutiérrezGCalvoIet al. Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy. Clin Cancer Res. (2017) 23:1227–35. 10.1158/1078-0432.CCR-16-0694

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72.

  PalugullaSDevarajuPKayalSNarayanSKMathaiyanJ. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients. Cancer Chemother Pharmacol. (2018) 82:421–8. 10.1007/s00280-018-3629-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73.

  StaffNPFehrenbacherJCCaillaudMDamajMISegalRARiegerS. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. (2020) 324:113121. 10.1016/j.expneurol.2019.113121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74.

  Gutierrez-CaminoAMartin-GuerreroILopez-LopezEEchebarria-BaronaAZabalzaIRuizIet al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. (2016) 26:100–2. 10.1097/FPC.0000000000000191

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75.

  ZgheibNKGhanemKMTamimHAridiCShahineRTarekNet al. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. (2018) 28:189–95. 10.1097/FPC.0000000000000345

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76.

  Martin-GuerreroIGutierrez-CaminoAEchebarria-BaronaAAstigarragaIGarcia de AndoinNNavajasAet al. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia. Pharmacogenomics J. (2019) 19:1–6. 10.1038/s41397-019-0081-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77.

  ZajaczkowskaRKocot-KepskaMLeppertWWrzosekAMikaJWordliczekJ. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. (2019) 20:1451. 10.3390/ijms20061451

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78.

  ArgyriouAAAntonacopoulouAGAlbertiPBrianiCBrunaJVelascoRet al. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst. (2019) 24:298–303. 10.1111/jns.12347

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79.

  PetersCMJimenez-AndradeJMJonasBMSevcikMAKoewlerNJGhilardiJRet al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. (2007) 203:42–54. 10.1016/j.expneurol.2006.07.022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80.

  VashisthaBSharmaAJainV. Ameliorative potential of ferulic acid in vincristine-induced painful neuropathy in rats: an evidence of behavioral and biochemical examination. Nutr Neurosci. (2017) 20:60–70. 10.1179/1476830514Y.0000000165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81.

  FlanaganJGVanderhaeghenP. The ephrins and Eph receptors in neural development. Annu Rev Neurosci. (1998) 21:309–45. 10.1146/annurev.neuro.21.1.309

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82.

  LiHSisoudiyaSDMartin-GiacaloneBAKhayatMMDugan-PerezSMarquez-DoDAet al. Germline cancer-predisposition variants in pediatric rhabdomyosarcoma: a report from the children's oncology group. J Natl Cancer Inst. (2021) 113:875–83. 10.1093/jnci/djaa204

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83.

  SchererSWFeinsteinDSOliveiraLTsuiLCPittlerSJ. Gene structure and chromosome localization to 7q213 of the human rod photoreceptor transducin gamma-subunit gene (GNGT1). Genomics. (1996) 35:241–3. 10.1006/geno.1996.0346

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84.

  LolliGJohnsonLN. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?Cell Cycle. (2005) 4:572–7. 10.4161/cc.4.4.1607

  • CrossRef
  • Google Scholar

• 85.

  DolanMEEl CharifOWheelerHEGamazonERArdeshir-Rouhani-FardSMonahanPet al. Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res. (2017) 23:5757–68. 10.1158/1078-0432.CCR-16-3224

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86.

  MielkeSSparreboomASteinbergSMGelderblomHUngerCBehringerDet al. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. (2005) 11:4843–50. 10.1158/1078-0432.CCR-05-0298

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87.

  HertzDLKidwellKMVangipuramKLiFPaiMPBurnessMet al. Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res. (2018) 24:3602–10. 10.1158/1078-0432.CCR-18-0656

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88.

  RowinskyEKJiroutekMBonomiPJohnsonDBakerSD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. (1999) 5:767–74.

  • Pubmed Abstract
  • Google Scholar

• 89.

  CromWRde GraafSSSynoldTUgesDRBloemhofHRiveraGet al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. (1994) 125:642–9. 10.1016/S0022-3476(94)70027-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90.

  van de VeldeMEPanettaJCWilhelmAJvan den BergMHvan der SluisIMvan den BosCet al. Population pharmacokinetics of vincristine related to infusion duration and peripheral neuropathy in pediatric oncology patients. Cancers. (2020) 12:1789. 10.3390/cancers12071789

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91.

  ApfelSCKesslerJA. Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres Clin Neurol. (1995) 4:593–606.

  • Pubmed Abstract
  • Google Scholar

• 92.

  YanMLiYZengHZhaoXWuHQianWet al. The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients. Hematology. (2020) 25:264–9. 10.1080/16078454.2020.1784615

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93.

  IbrahimEYEhrlichBE. Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol. (2020) 145:102831. 10.1016/j.critrevonc.2019.102831

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94.

  BoehmerleWSplittgerberULazarusMBMcKenzieKMJohnstonDGAustinDJet al. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci USA. (2006) 103:18356–61. 10.1073/pnas.0607240103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95.

  BoehmerleWZhangKSivulaMHeidrichFMLeeYJordtS-Eet al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci USA. (2007) 104:11103–8. 10.1073/pnas.0701546104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96.

  MoMErdelyiISzigeti-BuckKBenbowJHEhrlichBE. Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J. (2012) 26:4696–709. 10.1096/fj.12-214643

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97.

  WadiaRJStolarMGrensCEhrlichBEChaoHH. The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget. (2018) 9:7322–31. 10.18632/oncotarget.23467

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98.

  GouldSAWhiteMWilbreyALPórEColemanMPAdalbertR. Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1(-/-) mice. Exp Neurol. (2021) 338:113607. 10.1016/j.expneurol.2021.113607

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99.

  ChenYHSasakiYDiAntonioAMilbrandtJ. SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. Exp Neurol. (2021) 339:113636. 10.1016/j.expneurol.2021.113636

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100.

  GilchristLSMaraisLTannerL. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer. (2014) 22:359–66. 10.1007/s00520-013-1981-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101.

  ParkSBAlbertiPKolbNAGewandterJSSchenoneAArgyriouAA. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. (2019) 24(Suppl. 2):S13–s25. 10.1111/jns.12333

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102.

  MolassiotisAChengHLLeungKTLiYCWongKHAuJSKet al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. (2019) 9:e01312. 10.1002/brb3.1312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103.

  TanACMcCraryJMParkSBTrinhTGoldsteinD. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer. (2019) 27:4771–7. 10.1007/s00520-019-04781-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104.

  AlbertiPRossiECornblathDRMerkiesISPostmaTJFrigeniBet al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. (2014) 25:257–64. 10.1093/annonc/mdt409

  • Pubmed Abstract
  • CrossRef
  • Google Scholar